Chronic Pain News and Research

RSS

International Merchant Advisors signs LOI to purchase minority interest in Assured Pharmacy

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company has signed a letter of intent to purchase a minority interest in Assured Pharmacy, Inc. www.assuredpharmacyinc.com, a retail pharmaceutical operation that is focused on selling prescription medications in the chronic pain management medical sector.

16 Feb 2010

IMAI formally offered to purchase equity position in pharmaceutical operation

International Merchant Advisors, Inc. announced today that the company has formally offered to purchase an equity position in a pharmaceutical operation that is focused on selling in the chronic pain management medical sector.

15 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.

11 Feb 2010

Neurotoxin study may help find new therapies to block hyperactive ion channels

There are approximately 500 species of cone snails, each producing 50 - 200 different conotoxins. A similar number of peptide toxins are produced by snakes, spiders, sea anemones, scorpions and other venomous animals. The animals use the neurotoxins to paralyze their prey.

11 Feb 2010

Silver nanoparticles in higher-power, longer-life batteries for ICDs

Diamonds and gold may make some hearts flutter on Valentine's Day, but in a University at Buffalo laboratory, silver nanoparticles are being designed to do just the opposite.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

10 Feb 2010

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

In an aging society, falling is a growing problem. Just one bad fall can mark the start of a downward spiral in an older person's health and quality of life. The cost of treating falls also puts a heavy burden on the health care system. Toronto Rehab scientists have developed a simple footwear insole called SoleSensor(TM), which has proven to improve balance and prevent falls.

10 Feb 2010

Laser Spine Institute recognized as ‘Medical Partner of the Year’

This year, Gridiron Greats recognized LSI at the event as Medical Partner of the Year. LSI's medical director Dr. Michael Perry and CEO Bill Horne accepted the award.

10 Feb 2010

TI commences Phase IIa clinical trial for its lead molecule in CDH

Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.

10 Feb 2010

Study calls for effective intervention strategy for non-specific chest pain

Fewer than half of individuals who have "non-specific" chest pain (not explained by a well-known condition) experience relief from symptoms following standard medical care, according to a report in the February 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. In addition, one-tenth of those with persistent chest pain undergo potentially unnecessary diagnostic testing.

9 Feb 2010

Intrathecal drug delivery cost effective for chronic pain treatments

Estimates of pain care treatment costs exceed $1 billion annually in the United States. Today at the American Academy of Pain Medicine's 26th Annual Meeting two abstracts looked at the issue. One evaluated intrathecal drug delivery (a targeted medicine delivery system) that could save costs over time. The other analyzed the differences between the costs of treatment for chronic pain treatments.

5 Feb 2010

Hope for back pain: Minimally invasive facet arthrodesis and spinal cord stimulation

Results from the first prospective study of minimally invasive facet arthrodesis and long-term data on spinal cord stimulation demonstrate the viability of these options to achieve pain relief in patients with various back pain conditions. The studies were presented today at the American Academy of Pain Medicine's 26th Annual Meeting in San Antonio, TX.

5 Feb 2010

Findings reveal racial disparities in pain treatment outcomes

Findings from a retrospective analysis of a three-week treatment program for chronic pain revealed African Americans experienced worse outcomes compared to a matched group of Caucasians.

5 Feb 2010

Health Canada accepts AbstralTM New Drug Submission for review

Orexo AB today confirms that its partner, ProStrakan Group plc has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian Government Department with responsibility for public health.

4 Feb 2010

Results from three phase two studies show the effectiveness of Tanezumab

Tanezumab, a humanized monoclonal antibody that targets nerve-growth factor, reduced pain in three common pain conditions, according to the results from three phase two studies presented today in a single poster at the American Academy of Pain Medicine's 26th Annual Meeting.

4 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

CPS supports NACI recommendations for new shingles vaccine

The Canadian Pain Society (CPS) supports the National Advisory Committee on Immunization (NACI) recommendations for the use of a vaccine to significantly reduce the risk of developing herpes zoster (shingles) and post herpetic neuralgia in adults over the age of 60 without contraindications.

3 Feb 2010

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010